TFF Pharmaceuticals Announces Promising Topline Results from Phase 1 Clinical Trial of Inhaled Tacrolimus Powder and Progression Toward Phase 2 in Lung Transplantation

Inhaled Tacrolimus Shows Dose-Dependent PK that Achieves Desired Therapeutic Plasma Concentrations and Promising Safety Profile in both SAD and MAD Components of Phase 1

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

1 COMMENT

Cancel reply

Please enter your comment!
Please enter your name here